BioMarin Pharma (BMRN) Tops Q1 EPS by 39c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $65.68 +0.26%
EPS Growth %: +1,016.7%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
ANAB, ANIX, MNY, More
EPS Growth %: +1,016.7%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.71, $0.39 better than the analyst estimate of $0.32. Revenue for the quarter came in at $649 million versus the consensus estimate of $649.27 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $2.75-$2.95, versus the consensus of $2.75. BioMarin Pharma sees FY2024 revenue of $2.7-2.8 billion, versus the consensus of $2.76 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
- Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
- Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
